$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2017 Q3 Form 10-Q Financial Statement

#000114420417058300 Filed on November 13, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $200.0K $160.0K
YoY Change 25.0%
% of Gross Profit
Research & Development $87.73K $45.17K
YoY Change 94.2%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K
YoY Change -100.0%
% of Gross Profit
Operating Expenses $295.0K $212.5K
YoY Change 38.79%
Operating Profit -$295.0K -$212.5K
YoY Change 38.79%
Interest Expense $129.8K $1.971K
YoY Change 6484.37%
% of Operating Profit
Other Income/Expense, Net $242.8K -$1.971K
YoY Change -12419.48%
Pretax Income -$52.18K -$214.5K
YoY Change -75.67% 2045.14%
Income Tax
% Of Pretax Income
Net Earnings -$52.18K -$214.5K
YoY Change -75.67% 2045.14%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$367.90 -$1.598K
COMMON SHARES
Basic Shares Outstanding 106.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.00K $30.00K
YoY Change -33.33%
Cash & Equivalents $21.22K $33.46K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.22K $33.46K
YoY Change -36.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $188.8K $103.3K
YoY Change 82.79%
TOTAL ASSETS
Total Short-Term Assets $21.22K $33.46K
Total Long-Term Assets $188.8K $103.3K
Total Assets $210.0K $136.7K
YoY Change 53.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $160.0K $44.85K
YoY Change 256.75% 348.49%
Accrued Expenses $10.00K $2.822K
YoY Change 254.36%
Deferred Revenue
YoY Change
Short-Term Debt $250.0K $120.0K
YoY Change 108.33% -25.0%
Long-Term Debt Due $130.0K
YoY Change
Total Short-Term Liabilities $1.270M $446.0K
YoY Change 184.78% 147.75%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $30.00K
YoY Change -66.67%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $10.00K $30.00K
YoY Change -66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.270M $446.0K
Total Long-Term Liabilities $10.00K $30.00K
Total Liabilities $1.280M $471.9K
YoY Change 171.25% 162.16%
SHAREHOLDERS EQUITY
Retained Earnings -$572.1K
YoY Change
Common Stock $237.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.070M -$340.0K
YoY Change
Total Liabilities & Shareholders Equity $210.0K $136.7K
YoY Change 53.58%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$52.18K -$214.5K
YoY Change -75.67% 2045.14%
Depreciation, Depletion And Amortization $0.00 $10.00K
YoY Change -100.0%
Cash From Operating Activities -$280.0K -$120.0K
YoY Change 133.33%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $10.00K
YoY Change -1100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $100.0K -$10.00K
YoY Change -1100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 140.0K
YoY Change -35.71%
NET CHANGE
Cash From Operating Activities -280.0K -120.0K
Cash From Investing Activities 100.0K -10.00K
Cash From Financing Activities 90.00K 140.0K
Net Change In Cash -90.00K 10.00K
YoY Change -1000.0%
FREE CASH FLOW
Cash From Operating Activities -$280.0K -$120.0K
Capital Expenditures -$100.0K $10.00K
Free Cash Flow -$180.0K -$130.0K
YoY Change 38.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Liabilities
Liabilities
480303 USD
CY2017Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
0 USD
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25000 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
21216 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
221868 USD
CY2017Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2600 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2600 USD
CY2017Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
2707 USD
CY2016Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1439 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
189935 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
100644 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172748 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
748379 USD
dei Document Type
DocumentType
10-Q
CY2017Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
133481 USD
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2017Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
122514 USD
CY2016Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0 USD
CY2017Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
401461 USD
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2017Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
14402 USD
CY2016Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Operating Expenses
OperatingExpenses
931836 USD
us-gaap Net Income Loss
NetIncomeLoss
-1181889 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105885362 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Revenues
Revenues
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67566 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
493484 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6719 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q3 us-gaap Revenues
Revenues
0 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
87728 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
201985 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
294999 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-52182 USD
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
106313750 shares
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5286 USD
CY2016Q3 us-gaap Revenues
Revenues
0 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45174 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
164732 USD
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2637 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
212543 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-214514 USD
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100621359 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2017Q3 us-gaap Interest Expense
InterestExpense
129778 USD
CY2016Q3 us-gaap Interest Expense
InterestExpense
1971 USD
us-gaap Interest Expense
InterestExpense
195523 USD
us-gaap Interest Expense
InterestExpense
3837 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
242817 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1971 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-250053 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3837 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-571606 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90866349 shares
us-gaap Operating Expenses
OperatingExpenses
567769 USD
celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
0 USD
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-372595 USD
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
54530 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
144112 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
90713 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10845 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-69500 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-766902 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
566250 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-200652 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221868 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21216 USD
us-gaap Interest Paid Net
InterestPaidNet
11100 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
173578 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-54530 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
24284 USD
us-gaap Notes Assumed1
NotesAssumed1
0 USD
us-gaap Notes Assumed1
NotesAssumed1
20000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20565 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3757 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
280000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-259830 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
303186 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
33356 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33456 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
celz Proceeds From Subscription Receivable
ProceedsFromSubscriptionReceivable
50000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
735 USD
celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
5546 USD
celz Fair Value Of Warrants Issued In Private Placement
FairValueOfWarrantsIssuedInPrivatePlacement
8197 USD
us-gaap Stock Issued1
StockIssued1
100000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
130000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
90000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
125000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4314 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
376250 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2016Q2 celz Amount Of Debt Payable At Closing
AmountOfDebtPayableAtClosing
20000 USD
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
72808 USD
celz Employee Service Sharebased Compensation Nonvested Awards Expiration Period
EmployeeServiceSharebasedCompensationNonvestedAwardsExpirationPeriod
2021
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0086 pure
CY2017Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
585317 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
215886 USD
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
3600000 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
200000 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.25
CY2017Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
50000 USD
CY2017Q3 celz Working Capital Deficit
WorkingCapitalDeficit
1245894 USD
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3561467 shares
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106313750 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106313750 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
105013750 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
105013750 shares
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1689 USD
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
celz Class Of Warrant Or Right Conversion Ratio
ClassOfWarrantOrRightConversionRatio
one warrant to purchase another share of common stock at $0.10 per share for each ten shares purchased in the offering.
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></b> <font style="FONT-SIZE: 10pt"> &#150; The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. &#160;Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
100000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2500 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
166667 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.30
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-294999 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-212543 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-931836 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-567769 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-52182 USD
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-214514 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1181889 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-571606 USD

Files In Submission

Name View Source Status
0001144204-17-058300-index-headers.html Edgar Link pending
0001144204-17-058300-index.html Edgar Link pending
0001144204-17-058300.txt Edgar Link pending
0001144204-17-058300-xbrl.zip Edgar Link pending
celz-20170930.xml Edgar Link completed
celz-20170930.xsd Edgar Link pending
celz-20170930_cal.xml Edgar Link unprocessable
celz-20170930_def.xml Edgar Link unprocessable
celz-20170930_lab.xml Edgar Link unprocessable
celz-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv479116_10q.htm Edgar Link pending
tv479116_ex31-1.htm Edgar Link pending
tv479116_ex31-2.htm Edgar Link pending
tv479116_ex32-1.htm Edgar Link pending
tv479116_ex32-2.htm Edgar Link pending